IMV Inc.
IMVIQ
Other OTC0.00
USD
+0.00
- -
IMV Inc.
IMVIQ
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IMV Inc. (IMVIQ) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies using its proprietary DPX platform technology. The company offers a pipeline of product candidates including DPX-Survivac, an immunotherapy targeting survivin-expressing cancer cells for indications such as ovarian cancer and lymphoma; DPX-PDV, a preventive vaccine against human papillomavirus; and other investigational therapies leveraging the DPX delivery system for antigen-specific immune responses, which encapsulates antigens and adjuvants to achieve prolonged T-cell activation with minimal dosing requirements. IMV provides research and development services in immunotherapy formulation and immune response modulation, targeting oncologists, hospitals, and biotech partners in the immuno-oncology segment. Founded in 2000 and headquartered in Dartmouth, Nova Scotia, Canada, with additional operations in the United States and Europe, IMV serves global markets in North America, Europe, and Asia-Pacific through clinical trials and strategic collaborations. The company operates in the biotechnology industry, with business segments centered on immuno-oncology therapeutics and vaccine delivery technologies, catering primarily to patients with advanced solid tumors and hematological malignancies via partnerships with pharmaceutical firms. In the last two years, IMV has undergone significant changes including a ticker symbol update to IMVIQ reflecting its Nasdaq listing status amid strategic restructuring; completion of a reverse stock split and ongoing efforts to regain compliance with exchange requirements following financial challenges; advancement of DPX-Survivac into combination trials with checkpoint inhibitors like pembrolizumab, reporting promising phase 2 data in 2024 for platinum-resistant ovarian cancer; and formation of alliances with entities such as Merck for clinical development support, alongside cost-optimization measures including workforce reductions to extend cash runway into 2026. These developments underscore IMV's shift toward leaner operations and focused pipeline prioritization amid a challenging biotech funding environment.
Whitehawk Therapeutics (NASDAQ:WHWK) versus IMV (OTCMKTS:IMVIQ) Financial Review
Critical Comparison: NexImmune (NASDAQ:NEXI) vs. IMV (OTCMKTS:IMVIQ)